文献速递神经肿瘤

在BT-RADS中加入DSC PWI和DWI有助于识别高级别胶质瘤患者的术后复发

Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas.
PubMed 文献 · J Neurooncol · 2020-01-04

本研究纳入91例术后高级别胶质瘤且BT-RADS 3类病变患者,评估DSC PWI和DWI对BT-RADS鉴别肿瘤复发与非复发的附加价值。结果显示,51例为肿瘤复发,40例为非复发。在BT-RADS基础上加入DSC PWI或DWI均可提高诊断性能,三者联合诊断性能最佳。

要点

  • BT-RADS 3类病变中,51/91例为肿瘤复发,40/91例为非复发。
  • 加入DSC PWI后AUC从0.76升至0.90,加入DWI后AUC升至0.88。
  • BT-RADS联合DSC PWI和DWI的AUC达0.95,诊断性能最佳。

核心结论

  • 在BT-RADS 3类病变中,加入DSC PWI和DWI可显著提高鉴别肿瘤复发与非复发的诊断性能。

研究设计与样本

  • 本研究纳入91例术后高级别胶质瘤且BT-RADS 3类病变患者,测量rCBVmax和ADCmean,采用ROC曲线分析评估DSC PWI和DWI对BT-RADS的附加价值。

主要发现

  • 91例患者中51例为肿瘤复发,40例为非复发。
  • 肿瘤复发组与非复发组的rCBVmax和ADCmean存在显著差异。
  • BT-RADS单独诊断的AUC为0.76(95%CI 0.66-0.84);加入DSC PWI后AUC升至0.90(95%CI 0.81-0.95)。
  • 加入DWI后AUC升至0.88(95%CI 0.80-0.94)。
  • BT-RADS联合DSC PWI和DWI的AUC为0.95(95%CI 0.88-0.98),诊断性能最佳。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Brain Tumor Reporting and Data System (BT-RADS) category 3 is suitable for identifying cases with intermediate probability of tumor recurrence that do not meet the Response Assessment in Neuro-Oncology (RANO) criteria for progression. The aim of this study was to evaluate the added value of dynamic susceptibility contrast-enhanced perfusion-weighted imaging (DSC PWI) and diffusion-weighted imaging (DWI) to BT-RADS for differentiating tumor recurrence from non-recurrence in postoperative high-grade glioma (HGG) patients with category 3 lesions. METHODS: Patients with BT-RADS category 3 lesions were included. The maximal relative cerebral blood volume (rCBVmax) and the mean apparent diffusion coefficient (ADCmean) values were measured. The added value of DSC PWI and DWI to BT-RADS was evaluated by receiver operating characteristic (ROC) curve analysis. RESULTS: Fifty-one of 91 patients had tumor recurrence, and 40 patients did not. There were significant differences in rCBVmax and ADCmean between the tumor recurrence group and non-recurrence group. Compared to BT-RADS alone, the addition of DSC PWI to BT-RADS increased the area under curve (AUC) from 0.76 (95% confidence interval [CI] 0.66-0.84) to 0.90 (95% CI 0.81-0.95) for differentiating tumor recurrence from non-recurrence. The addition of DWI to BT-RADS increased the AUC from 0.76 (95% CI 0.66-0.84) to 0.88 (95% CI 0.80-0.94). The combination of BT-RADS, DSC PWI, and DWI exhibited the best diagnostic performance (AUC = 0.95; 95% CI 0.88-0.98) for differentiating tumor recurrence from non-recurrence. CONCLUSION: Adding DSC PWI and DWI to BT-RADS can significantly improve the diagnostic performance for differentiating tumor recurrence from non-recurrence in BT-RADS category 3 lesions.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Yang Y, Yang Y, Wu X, et al. Adding DSC PWI and DWI to BT-RADS can help identify postoperative recurrence in patients with high-grade gliomas. J Neurooncol. 2020. PMID: 31902040. doi:10.1007/s11060-019-03387-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。